47,110 Shares in Qiagen N.V. $QGEN Acquired by Strs Ohio

Key Points

• Strs Ohio has acquired a new stake in QIAGEN N.V., purchasing 47,110 shares worth approximately $1.89 million in the first quarter of the year.
• Several large investors have increased their holdings in QIAGEN, with institutional investors now owning 70% of the company's stock.
• Analysts have mixed ratings on QIAGEN, with target prices ranging from $49.00 to $55.00, and a consensus rating of "Hold".

Strs Ohio bought a new position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 47,110 shares of the company's stock, valued at approximately $1,891,000.

Other institutional investors also recently bought and sold shares of the company. Exchange Traded Concepts LLC boosted its position in shares of Qiagen by 2.3% in the 1st quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after buying an additional 395 shares in the last quarter. SVB Wealth LLC acquired a new stake in Qiagen in the first quarter valued at approximately $31,000. Walleye Trading LLC grew its position in Qiagen by 14.6% in the first quarter. Walleye Trading LLC now owns 7,367 shares of the company's stock valued at $296,000 after acquiring an additional 936 shares in the last quarter. Cetera Investment Advisers boosted its stake in shares of Qiagen by 14.4% during the 4th quarter. Cetera Investment Advisers now owns 11,297 shares of the company's stock valued at $505,000 after buying an additional 1,418 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Qiagen by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after buying an additional 1,425 shares during the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Trading Up 0.4%

Shares of QGEN stock traded up $0.17 on Friday, reaching $45.91. 560,901 shares of the stock were exchanged, compared to its average volume of 1,374,492. The stock has a market cap of $10.21 billion, a PE ratio of 27.15, a P/E/G ratio of 2.40 and a beta of 0.64. Qiagen N.V. has a one year low of $37.63 and a one year high of $51.88. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The stock has a 50 day moving average price of $48.27 and a 200 day moving average price of $44.78.

Qiagen (NYSE:QGEN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting analysts' consensus estimates of $0.60. The company had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The firm's quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.55 earnings per share. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Equities research analysts forecast that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Bank of America raised their price objective on Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Wall Street Zen lowered Qiagen from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. Cowen reiterated a "hold" rating on shares of Qiagen in a research report on Thursday, August 7th. Barclays initiated coverage on Qiagen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price objective for the company. Finally, UBS Group lifted their price target on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Three analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $49.69.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.